Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
535 Enrollment(s)
31 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Malignancies
RECRUITING
NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
51 Enrollment(s)
23 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Breast Carcinoma


Advanced Colon Carcinoma


Advanced Colorectal Carcinoma


Advanced Endometrial Carcinoma


Advanced Gastric Carcinoma


Advanced Gastroesophageal Junction Adenocarcinoma


Advanced Malignant Solid Neoplasm


Advanced Salivary Gland Carcinoma


Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Clinical Stage III Gastric Cancer AJCC v8


Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8


Clinical Stage IV Gastric Cancer AJCC v8


Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8


HER2-Positive Breast Carcinoma


Malignant Hepatobiliary Neoplasm


Metastatic Breast Carcinoma


Metastatic Colon Carcinoma


Metastatic Colorectal Carcinoma


Metastatic Endometrial Carcinoma


Metastatic Gastric Carcinoma


Metastatic Gastroesophageal Junction Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Salivary Gland Carcinoma


Stage III Colon Cancer AJCC v8


Stage III Colorectal Cancer AJCC v8


Stage III Major Salivary Gland Cancer AJCC v8


Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Stage IV Colon Cancer AJCC v8


Stage IV Colorectal Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Unresectable Breast Carcinoma


Unresectable Colon Carcinoma


Unresectable Colorectal Carcinoma


Unresectable Endometrial Carcinoma


Unresectable Gastric Carcinoma


Unresectable Gastroesophageal Junction Adenocarcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Salivary Gland Carcinoma
ACTIVE_NOT_RECRUITING
NCT03334617
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
527 Enrollment(s)
45 Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer
RECRUITING
NCT04482309
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
468 Enrollment(s)
123 Study location(s)
INTERVENTIONAL (PHASE2)
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer


Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
ACTIVE_NOT_RECRUITING
NCT03529110
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
524 Enrollment(s)
164 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT06819007
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
582 Enrollment(s)
19 Study location(s)
INTERVENTIONAL (PHASE3)
Ovarian Cancer
RECRUITING
NCT07073755
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
200 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Metastatic Breast Cancer


Drug Resistance


Hormone Receptor-Positive Breast Cancer


HER2-positive Breast Cancer


Triple-Negative Breast Cancer (TNBC)


Treatment Decisions
RECRUITING
NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
600 Enrollment(s)
233 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer